Navigation Links
Isis Initiates Phase 1 Study of ISIS-TTRRx and Earns $5 Million Milestone Payment From GlaxoSmithKline
Date:5/19/2011

AP, which affects more than 10,000 patients worldwide.  Patients with FAC have TTR build up in the heart muscle and succumb to heart failure five to six years after symptom onset.  Patients with FAP have TTR build up in peripheral nerve tissue leading to the loss of nerve function and wasting.  ISIS-TTRRx inhibits the production of all forms of TTR, offering a unique approach to treat all types of transthyretin-related amyloidosis.  

ABOUT ISIS PHARMACEUTICALS, INC.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners.  The Company has successfully commercialized the world's first antisense drug and has 24 drugs in development.  Isis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer.  Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases.  Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics.  Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing.  As an innovator in RNA-based drug discovery and development, Isis has designed and executed a patent strategy that has provided the Company with strong and extensive protection for Isis' drugs as well as all aspects of antisense drug discovery, development and manufacturing.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding Isis' collaboration with GlaxoSmithKline, the discovery, development and potential of drugs for severe and rare diseases, and the dev
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
2. Dendreon Initiates Second of Two New Phase 2 Trials of PROVENGE for Prostate Cancer
3. Emerging Growth Equities, Ltd. Initiates Coverage of CombiMatrix Corporation with a BUY Rating and an $18.00 Price Target
4. NovaRx Initiates Pivotal Phase III Clinical Trial in Lung Cancer Patients
5. CV Therapeutics Initiates Phase 1 Clinical Trial of CVT-3619, a Novel Potential Treatment for Cardiometabolic Diseases
6. Masimo Initiates Limited Release of First-Ever Noninvasive and Continuous Hemoglobin Monitors
7. Sinovac Initiates Clinical Trials for Inactivated Hepatitis A Vaccine in Ukraine
8. Orexigen(R) Therapeutics Initiates First Clinical Trial of OREX-003 for the Mitigation of Antipsychotic-Associated Weight Gain
9. SenesTech, Inc. Initiates Research Field Trials for ContraPest(R) in Indonesia
10. Portola Pharmaceuticals Initiates Phase II Trial of Betrixaban, its Novel Oral Factor Xa Inhibitor for Stroke Prevention in Atrial Fibrillation
11. Trinity Biotech Investor Group Initiates Campaign of ADR Conversion to Force a Special Meeting of Shareholders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... laureate Herbert Kroemer famously observed, referring to the ... where layers of different materials meet. In today,s ... of metal oxides are becoming increasingly prominent, with ... superconductors, ferroelectrics and multiferroics. Realizing the vast potential ...
(Date:1/15/2014)... Cynvenio, a cancer diagnostics company focused ... analysis of tumor cells in the bloodstream, today announced ... decision support application powered by CollabRx, Inc. , ... test, Therapy Finder will provide breast cancer patients and ...
(Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
(Date:1/15/2014)... 2014 Freeslate, Inc ., the ... that Lupin Limited, one of India’s top five pharmaceutical ... PharmD System for high throughput solid form screening. ... on a wide range of quality, affordable generic and ...
Breaking Biology Technology:A deeper look at interfaces 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... Alberta Centre for Advanced,MNT (Microsystems and Nanotechnology) Products ... Yallup as Chief Technology Officer. In this new,role ... within ACAMP to,build a world-class capability in Alberta ... technology devices, turning them into market-ready,commercial or industrial ...
... are not risk takers with their health, yet up to ... screenings,- 42 percent are at elevated risk for cardiovascular events, yet 20 percent, ... ... MORRISTOWN, N.J., Sept. 22 A new survey of men and,women age 40 ...
... F. Finn, Jr.,C.P.A. ("Finn"), Assignee of the assets of ... that all oral drug delivery,intellectual property will be sold ... The three presentations were:, 1. BIOROD -- ... Affecting the Bioadhesion Performance of,Spheromer III, 3. Pharmacokinetics ...
Cached Biology Technology:Chief Technology Officer Joins ACAMP 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 2Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 3Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 4Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 5Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 6Risky Business: New Survey Suggests Many Americans Live Dangerously, Even When They Say They Aren't 'Risk Takers' 7Spherics, Inc. Presented Three Key Technologies (BIOROD(TM), BIOGIT(TM), and SPHEROMER(TM)) at the 35th Annual Meeting of Controlled Release Society 2
(Date:4/20/2014)... corn crop residue to make ethanol and other biofuels ... than gasoline, according to a study published today in ... findings by a University of Nebraska-Lincoln team of researchers ... to meet federal mandates to ramp up ethanol production ... the stalks, leaves and cobs in cornfields after harvest ...
(Date:4/18/2014)... while feeding a world population predicted to reach ... approach to conservation that considers human-altered landscapes such ... and the natural habitat that supports it might ... where at least three-quarters of the land surface ... is vulnerable to human-caused impacts such as climate ...
(Date:4/18/2014)... soon as they,re planted may be good news for a ... the wild, a plant whose seeds sprouted at the first ... just an insurance policy against late frosts or unexpected dry ... too: Plants whose seeds put off sprouting until conditions ... a team of researchers working at the National Evolutionary Synthesis ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3Stanford researchers rethink 'natural' habitat for wildlife 2Stanford researchers rethink 'natural' habitat for wildlife 3Stanford researchers rethink 'natural' habitat for wildlife 4Plants with dormant seeds give rise to more species 2
... thrills among fossil collectors than a complete trilobite. These ... went extinct more than 250 million years ago, ... rare instances, an entire population of trilobites is found ... environment and behavior in these mass graves. Brett, ...
... the mechanical strength of cancer cell mucus layers provides ... suggests why some cancer cells are more resistant to ... of engineering at Northeastern University, Boston, Mass. ... protect against infection. Cancer cells, however, produce far more ...
... release is available in Spanish . ... growers find a replacement for methyl bromide are studying an ... ingredients. Researchers with USDA,s Agricultural Research Service (ARS) are ... microbial activity could be used to replace the popular fumigant. ...
Cached Biology News:Fossils record ancient migrations and trilobite orgies 2Breaking the mucus barrier unveils cancer cell secrets 2Alternatives eyed for methyl bromide 2
... cocktail of 3 siRNAs specifically targeted to ... popular product. The siTrio reagent guarantees you ... target gene when used under standard conditions ... of optimal transfection with one of B-Bridges ...
... Corticosterone kit is a competitive enzymeimmunoassay (EIA) ... mouse or rat serum or plasma. Corticosterone ... in rats and mice, and in most ... reptiles. Most mammals produce both corticosterone and ...
... This is a molecular screening, low melting ... molecular sieving. It is recommended for separation ... size such as PCR products. Micro ABgarose ... is not recommended for blotting techniques. At ...
Rabbit polyclonal to P5 ( Abpromise for all tested applications). entrezGeneID: 10954 SwissProtID: Q14554...
Biology Products: